Weibin WU

Prof. Weibin WU

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 November 2020 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
LWLimei Wan
Limei Wan
WWWeibin WU
Weibin WU
SJShunjun Jiang
Shunjun Jiang
SWShan he Wan
Shan he Wan
DMDongmei Meng
Dongmei Meng
PYPengjiu Yu
Pengjiu Yu
Recent studies have illuminated that blocking Ca2+ influx into effector cells is an attractive therapeutic strategy for lung injury. We hypothesize that T-type calcium channel may be a potential therapeutic target for acute lung injury (ALI). In this study, the pharmacological activity of mibefradil (a classical T-type calcium channel inhibitor) was assessed in a mouse model of lipopolysaccharide- (LPS-) induced ALI. In LPS challenged mice, mibefradil (20 and 40 mg/kg) dramatically decreased the total cell number, as well as the productions of TNF-α and IL-6 in bronchoalveolar lavage fluid (BALF). Mibefradil also suppressed total protein concentration in BALF, attenuated Evans blue extravasation, MPO activity, and NF-κB activation in lung tissue. Furthermore, flunarizine, a widely prescripted antimigraine agent with potent inhibition on T-type channel, was also found to protect mice against lung injury. These data demonstrated that T-type calcium channel inhibitors may be beneficial for treating acute lung injury. The important role of T-type calcium channel in the acute lung injury is encouraged to be further investigated.

13 June 2024 in Food Chemistry Advances
Verified
Journal Article
Open access
LYLimei Yu
Limei Yu
DWDongna Wen
Dongna Wen
MTMinhua Tan
Minhua Tan
BWBiying Wang
Biying Wang
WWWeibin WU
Weibin WU
YZYuanhong Zhang
Yuanhong Zhang

15 November 2025 in Iranian Journal of Pharmaceutical Research
Verified
Journal Article
Open access
NZNa Zhang
Na Zhang
XYXinjia Yang
Xinjia Yang
JLJiefei Liang
Jiefei Liang
CZChunyan Zhu
Chunyan Zhu
GSGuohua Shen
Guohua Shen
WWWeibin WU
Weibin WU
Background: Alveolar macrophages (AMs) play a pivotal role in the initiation, resolution, and tissue repair processes of pulmonary inflammatory diseases. The regulation of poly (ADP-ribose) polymerase-1 (PARP-1) is closely associated with inflammatory mechanisms, including the expression of inflammatory mediators, macrophage polarization, and mitochondrial damage. Tanshinone IIA, the primary active component of the Chinese herb Salvia miltiorrhiza Bge., exhibits potent anti-inflammatory activity. Objectives: This study aims to elucidate the mechanism by which tanshinone IIA inhibits macrophage polarization, attenuates the inflammatory response, and prevents mitochondrial damage through regulation of the PARP-1 signaling pathway. Methods: We investigated the effects of tanshinone IIA on macrophage polarization, inhibition of inflammation and oxidative stress, and protection against mitochondrial damage via the PARP-1 signaling pathway using various experimental approaches, including enzyme-linked immunosorbent assay (ELISA), flow cytometry, western blot analysis, molecular docking, and molecular dynamics (MD) simulation studies. Results: Compared with the model group, tanshinone IIA significantly inhibited the phosphorylation and activation of nuclear factor kappa B (NF-κB, P < 0.05) in AMs by modulating PARP-1 (P < 0.05). This modulation led to suppression of NLRP3 inflammasome activation (P < 0.05 versus the model group), ultimately inhibiting the release of inflammatory mediators such as nitric oxide (NO), interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α, P < 0.05). Simultaneously, tanshinone IIA suppressed cellular oxidative stress via the Nrf2/heme oxygenase-1 (HO-1) pathway (P < 0.05 versus the model group), resulting in decreased reactive oxygen species (ROS) release (P < 0.05) and reduced mitochondrial MitoSOX production (P < 0.05). By regulating PARP-1, tanshinone IIA also effectively inhibited mitochondrial damage (compared with the model group, JC-1 decreased and mitochondrial permeability transition (MPTP) increased, P < 0.05) and M1 polarization of AMs induced by lipopolysaccharide [LPS; expression of CD86, cyclooxygenase-2 (COX-2), and inducible nitric oxide synthase (iNOS) decreased; arginase-1 (ARG-1) and CD206 increased, P < 0.05]. Furthermore, it efficiently modulated signaling pathways involved in mitochondrial fission and fusion [optic atrophy 1 (OPA1), dynamin-related protein 1 (DRP1)] (P < 0.05). Conclusions: These findings suggest that the therapeutic effects of tanshinone IIA on pulmonary inflammation are closely related to its ability to inhibit inflammatory damage and oxidative stress, regulate AM polarization, and alleviate mitochondrial damage in AMs through modulation of the PARP-1 pathway.

24 November 2021 in Gastroenterology Research and Practice
Verified
Journal Article
Open access
PDF file
WWWeibin WU
Weibin WU
LLLiqiang Li
Liqiang Li
JYJian Yang
Jian Yang
PLPinyu Li
Pinyu Li
YHYuying Hu
Yuying Hu
XZXiaozhong Zhu
Xiaozhong Zhu
Aims. To explore the effects of Biejiaxiaozheng pills on carbon tetrachloride-induced hepatic fibrosis in rats through the NF-κB/Nrf2 pathway and to explore the possible antifibrotic mechanisms of the drug. Material and Method. A rat model of hepatic fibrosis was established via CCl4 induction. Liver function and antioxidant indices were detected using commercial kits. Hematoxylin-eosin and Masson staining were used to detect pathological changes in hepatic tissues. ELISA was used to measure plasma TNF-α, IL-β, and IL-6 levels. RT-PCR was used to measure changes in TNF-α, IL-β, and IL-6 levels in hepatic tissues. Changes in p65, P-p65, Nrf2, and HO-1 protein expression were detected using western blotting. Results. In rats with hepatic fibrosis, Biejiaxiaozheng pills effectively improved liver function, alleviated fibrosis in hepatic tissues, and significantly reduced collagen accumulation. The pills significantly downregulated inflammatory cytokine expression in hepatic tissues by suppressing p65 phosphorylation and reduced plasma inflammatory cytokine levels to some extent. The pills upregulated Nrf2 and HO-1 expression in hepatic tissues, enhanced antioxidant potential, and upregulated plasma antioxidant levels. Conclusion. Biejiaxiaozheng pills improved hepatic fibrosis symptoms and lesions in rats, likely by inhibiting the NF-κB pathway and promoting the Nrf2 pathway.

25 February 2025 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
CLChao Luo
Chao Luo
CCCong Chen
Cong Chen
NZNa Zhang
Na Zhang
JLJiani Li
Jiani Li
YLYaru Liang
Yaru Liang
KYKai Yang
Kai Yang

11 February 2025 in CyTA - Journal of Food
Verified
Journal Article
Open access
JLJiefei Liang
Jiefei Liang
WYWeiwei Yin
Weiwei Yin
DLDuanzhuo Li
Duanzhuo Li
MHMi Huang
Mi Huang
WSWenxia Si
Wenxia Si
WWWeibin WU
Weibin WU